A Phase 2 Randomized Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

A phase 2, randomized, placebo-controlled study designed to evaluate the efficacy and safety of repeated doses of evinacumab in adult patients with severe hypertriglyceridemia. The study consists of screening period (up to 37 days), a baseline/single-blind placebo run in period, a 12-week double-blind treatment period, a single-blind 12 week treatment period and an off-treatment follow-up period. Subjects will have the following procedures: blood work, LPL activity test, daily symptom questionnaire and a symptom/dietary impact questionnaire (hypertriglyceridemia and Acute Pancreatitis Signs and Symptoms), physical examiniation, ECG, MRI, and FDG-PET

You may be eligible for this study if you meet the following criteria:

• Conditions:
  TBD
• Age: - 99 Years
• Gender: All